New Insights into MASLD: The EVA1A-CD36 Axis Emerges as a Therapeutic Target
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), characterized by excessive lipid accumulation in liver cells, is a prevalent chronic liver condition globally. It is closely linked to insulin resistance, obesity, and diabetes, and can progress to severe liver conditions like steatohepatitis, cirrhosis, and hepatocellular carcinoma.
Current treatments for MASLD are limited to lifestyle and dietary adjustments, with no effective drug therapies.
The dysregulation of hepatic lipid metabolism, primarily due to an imbalance in lipid acquisition and utilization, is a key factor in MASLD. Fatty acid uptake, a critical step, is facilitated by transporters such as CD36, which can undergo modifications like palmitoylation. This dynamic palmitoylation regulates fatty acid uptake by influencing CD36's membrane localization.
Discovering the EVA1A-CD36 Axis
A recent study led by Associate Professor Ning Li at Qingdao University investigated the regulation of CD36. The research revealed that the tumor suppressor gene EVA1A regulates CD36 expression and palmitoylation in hepatocellular carcinoma, positioning EVA1A as a key regulator of hepatic lipid metabolism.
The findings propose the 'EVA1A-CD36 axis' as a novel pathogenic mechanism and a potential therapeutic target for MASLD.
Key Findings from the Study
The research uncovered several critical insights into the role of EVA1A in hepatic lipid metabolism and MASLD progression:
EVA1A Downregulation in Fatty Liver Disease
In liver tissue from patients with hepatocellular carcinoma and co-occurring fatty liver disease, EVA1A expression was significantly reduced. Furthermore, mice with liver-specific Eva1a knockout developed pronounced hepatic steatosis and exhibited disrupted fat and fatty acid metabolism, indicating that EVA1A deficiency directly contributes to hepatic lipid dysregulation.
EVA1A Restoration Improves Steatosis
In ob/ob mice, a model for hereditary obesity and fatty liver, restoring hepatic Eva1a expression through adeno-associated virus (AAV-Eva1a) injection significantly mitigated liver steatosis. This intervention also led to a reduction in the fatty acid transporter CD36 in the liver.
Dual Regulation of CD36 by EVA1A
EVA1A exerts its influence on CD36 through two distinct mechanisms:
- Transcriptional Level: Reduced EVA1A activates the mTORC1-PPARγ2 signaling pathway, which in turn increases the transcription of CD36. This leads to higher production of the CD36 protein.
- Post-translational Modification Level: Decreased EVA1A inhibits the transcription of the depalmitoylation enzyme APT1 and enhances the transcription of palmitoyl acyltransferases ZDHHC4/5. This promotes the palmitoylation of CD36.
Altered CD36 Localization and Function
The changes in CD36 palmitoylation have significant functional consequences:
- Palmitoylation shifts CD36 to the plasma membrane, increasing fatty acid uptake into liver cells.
- Simultaneously, it decreases CD36 presence on mitochondria, thereby impairing fatty acid β-oxidation, the process by which fatty acids are broken down for energy.
These combined effects of increased uptake and reduced breakdown exacerbate lipid accumulation in the liver, contributing to the pathology of MASLD. The identification of the EVA1A-CD36 axis provides a promising avenue for future therapeutic development.